Previous 10 | Next 10 |
NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. ...
BOSTON and LONDON, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of long-acting PASylated ®...
BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development...
2023-10-20 16:41:52 ET More on Akari Therapeutics Akari Therapeutics announces existing investors support the company through $2M private placement financing Seeking Alpha’s Quant Rating on Akari Therapeutics Financial information for Akari Therapeutics ...
Trinity Biotech plc (TRIB) is expected to report $-0.07 for Q3 2023 Vicapsys Life Sciences Inc (VICP) is expected to report for quarter end 2023-06-30 Innotech Corp (INTH) is expected to report for quarter end 2023-06-30 Village Super Market Inc. Class A Common Stock (VLGEA) is expect...
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult HSCT-TMA and start PAS-nomacopan clinical trials in geographic atrophy (GA) Granted orphan drug designation from the European Commission...
Nanobiotix S.A. (NBTX) is expected to report for Q2 2023 Wal-mart de Mexico S A B de C V ADR (WMMVY) is expected to report for Q2 2023 Bion Environmental Technologies Inc. (BNET) is expected to report for Q1 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-...
Akari Therapeutics Plc (AKTX) is expected to report $0 for Q2 2023
2023-09-21 11:53:10 ET More on Akari Therapeutics Seeking Alpha’s Quant Rating on Akari Therapeutics Financial information for Akari Therapeutics For further details see: Akari Therapeutics announces existing investors support the company through $2M ...
BOSTON and LONDON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it has entered into ...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies...
Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophth...